Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB3 | P54753 | 16/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2877098 | 0.91 | EPHB3 (0.98) | EPHB3RIPK2LCKIRAK4 | |
| SCHEMBL2875231 | 0.90 | EPHB3 (1.00) | EPHB3RIPK2LCKIRAK4 | |
| SCHEMBL2874133 | 0.81 | EPHB3 (1.00) | EPHB3RIPK2LCK | |
| SCHEMBL2873995 | 0.79 | EPHB3 (1.00) | EPHB3RIPK2LCK | |
| SCHEMBL17437883 | 0.78 | EPHB3 (0.63) | EPHB3KDM4EKMT2A | |
| SCHEMBL2878098 | 0.78 | EPHB3 (1.00) | EPHB3RIPK2LCKIRAK4 | |
| SCHEMBL17454455 | 0.77 | EPHB3 (0.62) | EPHB3IRAK4FLT3 | |
| SCHEMBL27431439 | 0.77 | EPHB3 (0.62) | EPHB3IRAK4FLT3 | |
| SCHEMBL22170113 | 0.77 | EPHB3 (1.00) | EPHB3RIPK2LCK | |
| SCHEMBL2879861 | 0.76 | EPHB3 (0.73) | EPHB3RIPK2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010117787-A2 | INHIBITING EPH B-3 KINASE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2010-10-14 | — | — | WO | claimed |
| US-8927545-B2 | Inhibiting Eph B-3 kinase | DUKE UNIVERSITY (US) | 2015-01-06 | — | — | US | disclosed |
| US-20120238597-A1 | Inhibiting EPH B-3 Kinase | DUKE UNIVERSITY (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2010117787-A2 | INHIBITING EPH B-3 KINASE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238597-A1 | Inhibiting EPH B-3 Kinase | EPHB3, EPHB1, EPHB2 | EPHB3 1/4885RIPK2 173/4885LCK 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.